Introduction The epidermal growth factor receptor (EGFR) inhibitor erlotinib is much less
effective in non–small-cell lung cancer (NSCLC) tumors with wild-type EGFR, than in tumors …

Purpose Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in non-small cell lung
cancer (NSCLC). Autophagy is a catabolic process in response to stress and deprivation of …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized
the treatment for non-small cell lung cancer patients, but acquired resistance limit the …

Abstract epidermal growth factor receptor (EGFR) somatic mutations are found in the
majority of non‑small‑cell lung cancers (NSCLCs) and patients with NSCLC who harbor …

Epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib have been
widely used in patients with non-small-cell lung cancer. Unfortunately, the efficacy of EGFR …

Background Four large clinical trials have shown that concurrent administration of an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or …

Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent
against cancer due to its relatively low side-effect profile and, at times, greater efficacy …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,
are effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations …

Although non-small cell lung cancer (NSCLC) patients with EGFR mutation positive (EGFR
M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the …

The development of therapeutic resistance to EGFR tyrosine kinase inhibitors (EGFR‐TKIs,
ie erlotinib or gefitinib) has been the major clinical problem when treating lung …